HRP20200872T1 - Kombinacija čistih antagonista 5-ht6 receptora sa inhibitorima acetilholinesteraze - Google Patents
Kombinacija čistih antagonista 5-ht6 receptora sa inhibitorima acetilholinesteraze Download PDFInfo
- Publication number
- HRP20200872T1 HRP20200872T1 HRP20200872TT HRP20200872T HRP20200872T1 HR P20200872 T1 HRP20200872 T1 HR P20200872T1 HR P20200872T T HRP20200872T T HR P20200872TT HR P20200872 T HRP20200872 T HR P20200872T HR P20200872 T1 HRP20200872 T1 HR P20200872T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- piperazinyl
- sulfonyl
- methoxy
- indole
- Prior art date
Links
- 239000000544 cholinesterase inhibitor Substances 0.000 title claims 9
- 108091005435 5-HT6 receptors Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 22
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 16
- GWCYPEHWIZXYFZ-UHFFFAOYSA-N masupirdine Chemical compound C12=CC(OC)=CC=C2N(S(=O)(=O)C=2C(=CC=CC=2)Br)C=C1CN1CCN(C)CC1 GWCYPEHWIZXYFZ-UHFFFAOYSA-N 0.000 claims 13
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 8
- 229960003530 donepezil Drugs 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 4
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 4
- 229960004136 rivastigmine Drugs 0.000 claims 4
- 239000003751 serotonin 6 antagonist Substances 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 229960003980 galantamine Drugs 0.000 claims 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- XKDCUJBWVGDNSH-UHFFFAOYSA-N 1-(2-bromophenyl)sulfonyl-5-methoxy-3-[(4-methylpiperazin-1-yl)methyl]indole;methanesulfonic acid;hydrate Chemical group O.CS(O)(=O)=O.CS(O)(=O)=O.C12=CC(OC)=CC=C2N(S(=O)(=O)C=2C(=CC=CC=2)Br)C=C1CN1CCN(C)CC1 XKDCUJBWVGDNSH-UHFFFAOYSA-N 0.000 claims 1
- PIQRFUCZSGOHKB-UHFFFAOYSA-N 1-(4-fluorophenyl)sulfonyl-5-methoxy-3-[(4-methylpiperazin-1-yl)methyl]indole Chemical compound C12=CC(OC)=CC=C2N(S(=O)(=O)C=2C=CC(F)=CC=2)C=C1CN1CCN(C)CC1 PIQRFUCZSGOHKB-UHFFFAOYSA-N 0.000 claims 1
- MZPDNMSIIFZBTH-UHFFFAOYSA-N 1-(4-fluorophenyl)sulfonyl-5-methoxy-3-[(4-methylpiperazin-1-yl)methyl]indole dihydrochloride Chemical compound Cl.Cl.COc1ccc2n(cc(CN3CCN(C)CC3)c2c1)S(=O)(=O)c1ccc(F)cc1 MZPDNMSIIFZBTH-UHFFFAOYSA-N 0.000 claims 1
- KEPYHFKGGRLKPU-UHFFFAOYSA-N 5-methoxy-3-[(4-methylpiperazin-1-yl)methyl]-1-(4-propan-2-ylphenyl)sulfonylindole Chemical compound C12=CC(OC)=CC=C2N(S(=O)(=O)C=2C=CC(=CC=2)C(C)C)C=C1CN1CCN(C)CC1 KEPYHFKGGRLKPU-UHFFFAOYSA-N 0.000 claims 1
- MYIZVVVLXBGPQY-UHFFFAOYSA-N 5-methoxy-3-[(4-methylpiperazin-1-yl)methyl]-1-(4-propan-2-ylphenyl)sulfonylindole dihydrochloride Chemical compound Cl.Cl.COc1ccc2n(cc(CN3CCN(C)CC3)c2c1)S(=O)(=O)c1ccc(cc1)C(C)C MYIZVVVLXBGPQY-UHFFFAOYSA-N 0.000 claims 1
- 229960003135 donepezil hydrochloride Drugs 0.000 claims 1
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical group [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- -1 salt 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/305—Mercury compounds
- A61K31/31—Mercury compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Claims (17)
1. Kombinacija, naznačena time, što sadrži čisti antagonist 5-HT6 receptora i inhibitor acetilkolinesteraze; pri čemu:
čisti antagonist 5-HT6 receptora se bira između
1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indola;
1-[(4-fluorofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indola; i
1-[(4-izopropilfenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indola;
ili farmaceutski prihvatljive soli istog.
2. Kombinacija kako je navedeno u patentnom zahtjevu 1, naznačena time, što je čisti antagonist 5-HT6 receptora 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indol ili njegova farmaceutski prihvatljiva sol.
3. Kombinacija kako je navedeno u patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačena time, što se farmaceutski prihvatljiva sol čistog antagonista 5-HT6 receptora bira između 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indol dimezilat monohidrata; 1-[(4-fluorofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indol dihidroklorida; i 1-[(4-izopropilfenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indol dihidroklorida.
4. Kombinacija kako je navedeno u patentnom zahtjevu 1, naznačena time, što se inhibitor acetilkolinesteraze bira između donepezila, galantamina i rivastigmina ili farmaceutski prihvatljive soli istog.
5. Kombinacija kako je navedeno u patentnom zahtjevu 1 ili patentnom zahtjevu 4, naznačena time, što se inhibitor acetilkolinesteraze bira između donepezila i rivastigmina ili farmaceutski prihvatljive soli istog ili je inhibitor acetilkolinesteraze ili njegova farmaceutski prihvatljiva sol donepezil hidroklorid.
6. Kombinacija kako je navedeno u bilo kojem od patentnih zahtjeva 1 do 5, za upotrebu u liječenju kognitivnih poremećaja kod pacijenta, poželjno pri čemu se kognitivni poremećaj bira između Alzheimerove bolesti, šizofrenije, Parkinsonove bolesti, demencije sa Lewyjevim tijelima, vaskularne demencije i frontotemporalne demencije.
7. Spoj 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indol ili njegova farmaceutski prihvatljiva sol za upotrebu u kombinaciji sa inhibitorom acetilkolinesteraze za liječenje Alzheimerove bolesti kod pacijenta.
8. Spoj za upotrebu prema patentnom zahtjevu 7, kao dodatno liječenje kod pacijenta koji je na stabilnom liječenju inhibitorom acetilkolinesteraze.
9. Spoj za upotrebu kako je navedeno u patentnom zahtjevu 7 ili patentnom zahtjevu 8, naznačen time, što se inhibitor acetilkolinesteraze bira između donepezila, galantamina i rivastigmina ili farmaceutski prihvatljive soli istog, ili je inhibitor acetilkolinesteraze donepezil i rivastigmin ili farmaceutski prihvatljiva sol istog.
10. Spoj za upotrebu kako je navedeno u patentnom zahtjevu 7 ili patentnom zahtjevu 8, naznačen time, što je 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indol ili njegova farmaceutski prihvatljiva sol 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indol dimezilat monohidrat.
11. Spoj za upotrebu kako je navedeno u patentnom zahtjevu 9, naznačen time, što liječenje uključuje primjenu kod pacijenta:
(a) 1 mg do 200 mg 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indola ili njegove farmaceutski prihvatljive soli na dan; ili
(b) gdje liječenje uključuje primjenu kod pacijenta 1 mg do 10 mg 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indola ili njegove farmaceutski prihvatljive soli na dan; ili
(c) gdje liječenje uključuje primjenu kod pacijenta 25 mg do 125 mg 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indola ili njegove farmaceutski prihvatljive soli na dan; ili
(d) gdje liječenje uključuje primjenu kod pacijenta 150 mg do 200 mg 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indola ili njegove farmaceutski prihvatljive soli na dan; ili
(e) gdje liječenje uključuje primjenu kod pacijenta 25 mg do 75 mg 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indola ili njegove farmaceutski prihvatljive soli na dan; ili
(f) gdje liječenje uključuje primjenu kod pacijenta 75 mg do 150 mg 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indola ili njegove farmaceutski prihvatljive soli na dan; ili
(g) gdje liječenje uključuje primjenu kod pacijenta 1 mg do 30 mg donepezila ili njegove farmaceutski prihvatljive soli na dan, ili
(h) gdje liječenje uključuje primjenu kod pacijenta 5 mg do 25 mg donepezila ili njegove farmaceutski prihvatljive soli na dan, ili
(i) gdje liječenje uključuje primjenu kod pacijenta 10 mg do 25 mg donepezila ili njegove farmaceutski prihvatljive soli na dan.
12. Farmaceutski pripravak, naznačen time, što uključuje kombinaciju kako je navedeno u bilo kojem od patentnih zahtjeva 1 do 5, i farmaceutski prihvatljive ekscipijente ili kombinaciju istog.
13. Farmaceutski pripravak kako je navedeno u patentnom zahtjevu 12, za upotrebu u liječenju kognitivnih poremećaja koji se biraju između Alzheimerove bolesti, šizofrenije, Parkinsonove bolesti, demencije sa Lewyjevim tijelima, vaskularne demencije i frontotemporalne demencije.
14. Farmaceutski pripravak kako je navedeno u patentnom zahtjevu 12 ili patentnom zahtjevu 13, naznačen time, što su 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indol ili njegova farmaceutski prihvatljiva sol prisutni:
(a) u količini od 1 mg do 300 mg, ili
(b) u količini od 35 mg do 200 mg, ili
(c) u količini od 200 mg do 300 mg, ili
(d) u količini od 75 mg ili 150 mg.
15. Farmaceutski pripravak kako je navedeno u patentnom zahtjevu 12 ili patentnom zahtjevu 13, naznačen time, što su donepezil ili njegova farmaceutski prihvatljiva sol prisutni u količini od:
(a) 2 mg do 30 mg, ili
(b) količini od 5 mg do 25 mg, ili
(c) u količini od 5 mg, ili
(d) u količini od 10 mg, ili
(e) u količini od 23 mg.
16. Spoj za upotrebu kako je navedeno u patentnom zahtjevu 7, naznačen time, što liječenje uključuje primjenu 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indola ili njegove farmaceutski prihvatljive soli kod pacijenta oralnim, nazalnim, lokalnim, dermalnim ili parenteralnim putem.
17. Spoj za upotrebu kako je navedeno u patentnom zahtjevu 7, naznačen time, što liječenje uključuje primjenu 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indola ili njegove farmaceutski prihvatljive soli kod pacijenta jednom do tri puta dnevno, jednom do tri puta tjedno ili jednom do tri puta mjesečno.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641017205 | 2016-05-18 | ||
| EP16766622.1A EP3484467B1 (en) | 2016-05-18 | 2016-08-03 | Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors |
| PCT/IB2016/054673 WO2017199071A1 (en) | 2016-05-18 | 2016-08-03 | Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200872T1 true HRP20200872T1 (hr) | 2020-11-27 |
Family
ID=56940098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200872TT HRP20200872T1 (hr) | 2016-05-18 | 2020-06-02 | Kombinacija čistih antagonista 5-ht6 receptora sa inhibitorima acetilholinesteraze |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US11458135B2 (hr) |
| EP (1) | EP3484467B1 (hr) |
| JP (1) | JP6606299B2 (hr) |
| KR (1) | KR102015484B1 (hr) |
| CN (2) | CN114642667A (hr) |
| AU (1) | AU2016407427B2 (hr) |
| BR (1) | BR112018073419A2 (hr) |
| CA (1) | CA3023819C (hr) |
| CY (1) | CY1123013T1 (hr) |
| DK (1) | DK3484467T3 (hr) |
| EA (1) | EA036347B1 (hr) |
| ES (1) | ES2796181T3 (hr) |
| HR (1) | HRP20200872T1 (hr) |
| HU (1) | HUE050819T2 (hr) |
| IL (1) | IL262921B (hr) |
| LT (1) | LT3484467T (hr) |
| MA (1) | MA45639B1 (hr) |
| MD (1) | MD3484467T2 (hr) |
| ME (1) | ME03731B (hr) |
| MX (1) | MX2018014185A (hr) |
| NZ (1) | NZ748280A (hr) |
| PL (1) | PL3484467T3 (hr) |
| PT (1) | PT3484467T (hr) |
| RS (1) | RS60422B1 (hr) |
| SG (1) | SG11201809856SA (hr) |
| SI (1) | SI3484467T1 (hr) |
| WO (1) | WO2017199071A1 (hr) |
| ZA (1) | ZA201807468B (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111084768A (zh) * | 2018-10-24 | 2020-05-01 | 中国科学院昆明动物研究所 | 吉非罗齐及其衍生物用于治疗和/或预防神经退行性疾病的用途 |
| CN111084776A (zh) * | 2018-10-24 | 2020-05-01 | 中国科学院昆明动物研究所 | 匹立尼酸及其衍生物用于治疗和/或预防神经退行性疾病的用途 |
| JP2023506724A (ja) * | 2019-12-02 | 2023-02-20 | スヴェン・ライフ・サイエンシーズ・リミテッド | 認知症患者の行動心理学的症状の治療 |
| CA3162938A1 (en) * | 2019-12-02 | 2021-06-10 | Suven Life Sciences Limited | Methods for treating behavioral and psychological symptoms in patients with dementia |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4559230B2 (ja) * | 2002-11-28 | 2010-10-06 | スベン ライフ サイエンシズ リミティド | セロトニン受容体に対する親和性を有する新規ｎ−アリールスルホニル−３−置換されたインドール、その調製方法、それを含有する医薬組成物 |
| PE20071143A1 (es) | 2006-01-13 | 2008-01-20 | Wyeth Corp | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
| ES2366958T3 (es) * | 2006-06-23 | 2011-10-27 | Laboratorios Del Dr. Esteve, S.A. | Combinación de un inhibidor de la colinesterasa y un compuesto con afinidad por el receptor 5-ht6. |
| AR061637A1 (es) | 2006-06-26 | 2008-09-10 | Epix Delaware Inc | Composiciones y metodos de tratamiento de trastornos del snc |
| JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
| CA2929309C (en) * | 2013-12-02 | 2018-07-03 | Suven Life Sciences Limited | Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate |
-
2016
- 2016-08-03 KR KR1020187035983A patent/KR102015484B1/ko active IP Right Grant
- 2016-08-03 CN CN202210321209.2A patent/CN114642667A/zh active Pending
- 2016-08-03 NZ NZ748280A patent/NZ748280A/en unknown
- 2016-08-03 AU AU2016407427A patent/AU2016407427B2/en active Active
- 2016-08-03 ES ES16766622T patent/ES2796181T3/es active Active
- 2016-08-03 BR BR112018073419-5A patent/BR112018073419A2/pt not_active Application Discontinuation
- 2016-08-03 MA MA45639A patent/MA45639B1/fr unknown
- 2016-08-03 PL PL16766622T patent/PL3484467T3/pl unknown
- 2016-08-03 CA CA3023819A patent/CA3023819C/en active Active
- 2016-08-03 ME MEP-2020-109A patent/ME03731B/me unknown
- 2016-08-03 RS RS20200635A patent/RS60422B1/sr unknown
- 2016-08-03 SI SI201630791T patent/SI3484467T1/sl unknown
- 2016-08-03 SG SG11201809856SA patent/SG11201809856SA/en unknown
- 2016-08-03 US US16/099,161 patent/US11458135B2/en active Active
- 2016-08-03 JP JP2018559336A patent/JP6606299B2/ja active Active
- 2016-08-03 EP EP16766622.1A patent/EP3484467B1/en active Active
- 2016-08-03 WO PCT/IB2016/054673 patent/WO2017199071A1/en unknown
- 2016-08-03 EA EA201892529A patent/EA036347B1/ru unknown
- 2016-08-03 HU HUE16766622A patent/HUE050819T2/hu unknown
- 2016-08-03 LT LTEP16766622.1T patent/LT3484467T/lt unknown
- 2016-08-03 PT PT167666221T patent/PT3484467T/pt unknown
- 2016-08-03 DK DK16766622.1T patent/DK3484467T3/da active
- 2016-08-03 CN CN201680085574.0A patent/CN109069468A/zh active Pending
- 2016-08-03 MX MX2018014185A patent/MX2018014185A/es unknown
- 2016-08-03 MD MDE20190594T patent/MD3484467T2/ro unknown
-
2018
- 2018-11-07 ZA ZA2018/07468A patent/ZA201807468B/en unknown
- 2018-11-11 IL IL262921A patent/IL262921B/en active IP Right Grant
-
2020
- 2020-05-29 CY CY20201100489T patent/CY1123013T1/el unknown
- 2020-06-02 HR HRP20200872TT patent/HRP20200872T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200872T1 (hr) | Kombinacija čistih antagonista 5-ht6 receptora sa inhibitorima acetilholinesteraze | |
| HRP20201412T1 (hr) | Trostruka kombinacija čistih antagonista receptora 5-ht6, inhibitora acetilkolinesteraze i antagonista receptora nmda | |
| HRP20210640T1 (hr) | Kombinacija čistih 5-ht6 antagonista receptora sa nmda antagonistom receptora | |
| HRP20110524T1 (hr) | Spojevi dihidropiridina za neurodegenerativne bolesti i demenciju | |
| JP2009541443A5 (hr) | ||
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| DE602008005582D1 (de) | Pyrazolderivate als p2x7-modulatoren | |
| MA32692B1 (fr) | Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin | |
| WO2018042362A9 (en) | Muscarinic m1 receptor positive allosteric modulators | |
| HRP20171977T1 (hr) | Derivati dolastatina 10 i auristatina | |
| HRP20161277T1 (hr) | Pripravci za liječenje centralno posredovane mučnine i povraćanja | |
| JP2016147915A5 (hr) | ||
| HRP20130007T1 (hr) | Lijeäśenje kognitivnih poremeä†aja pomoä†u (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamida i njegovih farmaceutski prihvatljivih soli | |
| PE20150671A1 (es) | Antagonistas del receptor de 5-ht3 | |
| HRP20201152T1 (hr) | Kondenzirani benzazepin za liječenje mucanja | |
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| JP2013518914A5 (hr) | ||
| MX2016009581A (es) | Derivados de 6-fenil- o 6-(piridin-3-il) indazol y metodos de uso. | |
| PH12019500154A1 (en) | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof | |
| EA036542B9 (ru) | Галоген-замещенные пиперидины в качестве модуляторов орексинового рецептора | |
| HRP20221344T1 (hr) | Novi pripravak acetaminofenskog spoja bez nuspojave po jetru | |
| EA201592247A1 (ru) | 4-(5-(4-ХЛОРОФЕНИЛ)-2-(2-ЦИКЛОПРОПИЛАЦЕТИЛ)-1,4-ДИМЕТИЛ-1H-ПИРРОЛ-3-ИЛ)БЕНЗОЛСУЛЬФОНАМИД В КАЧЕСТВЕ МОДУЛЯТОРА АЛЬФА-7 nAChR | |
| MX2019010993A (es) | Derivados de tetrahidroquinolina como antagonistas del receptor p2x7. | |
| WO2012002583A1 (en) | Method for treating schizophrenia and related diseases with a combination therapy | |
| HRP20201262T1 (hr) | Kombinacija inverzivnih agonista histamin-3 receptora sa inhibitorima acetilkolinesteraze |